# PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

- Link: https://www.thailand-business-news.com/pr-news/pepromene-bio-announces-oral-presentation-at-eha-2026-highlighting-favorable-safety-and-durable-responses-with-pmb-ct01-baff-r-car-t-cell-therapy-in-b-cell-lymphomas-including-after-prior-cd19-car
- Published: 2026-05-28T18:00:00+07:00
- Author: PR Newswire

|   |

IRVINE, Calif., May 28, 2026 /PRNewswire/ — PeproMene Bio, Inc. announced today 
that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an
investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy,
have been selected for an oral presentation at the 2026 Congress of the European
Hematology Association (EHA).

This presentation will highlight results from the completed dose-escalation portion
of the study in relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), including
patients whose cancer has progressed following standard CD19-directed CAR T-cell
therapy ([NCT05370430](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4696860-1&h=3758431543&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05370430%3Fterm%3DNCT05370430%26viewType%3DCard%26rank%3D1&a=NCT05370430)).

Among the nine patients treated in this phase, PMB-CT01 demonstrated a promising
safety profile with no dose-limiting toxicities, no grade >1 cytokine release syndrome(
CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS).
Seven of nine patients (78%) achieved a complete response (CR). At the last data
cutoff, no relapses had occurred and all responses remained ongoing, with the longest
response exceeding 3 years. Responding patients also achieved minimal residual disease(
MRD)-negative status, indicating deep remissions with no detectable residual cancer
cells.

Building on these results, the trial is actively enrolling patients into expansion
cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma(
FL). Importantly, the first patient treated in this expansion phase – a patient 
with transformed FL (tFL) who had progressed following CD19 CAR T therapy – achieved
a CR at their first disease assessment. tFL is an aggressive form of lymphoma with
limited established treatment options.

"When cancer progresses following CD19 CAR T therapy, patients face a significant
unmet medical need, with very limited treatment options remaining," said Larry W.
Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. "These durable CRs clinically
validate BAFF-R as a novel target, while the favorable safety profile observed to
date may support future use in outpatient community oncology settings and further
exploration in refractory autoimmune diseases."

**Presentation Details**

**Abstract Title:** Durable responses and favorable safety of BAFF-R CAR T-cells(
PMB-CT01) in patients with relapsed/refractory B-cell lymphomas with prior CD19-
directed therapy failure or CD19-negative disease

**Abstract:** [EHA-1611 S287](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4696860-1&h=1619890347&u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2026%2Feha-2026%2F4206841%2Fl.elizabeth.budde.durable.responses.and.favorable.safety.of.baff-r.car.t-cells.html%3Ff%3Dlisting%253D0%252Abrowseby%253D8%252Asortby%253D2%252Atopic%253D1574%252Asearch%253DCAR&a=EHA-1611+S287)

**Date/Time:** June 14, 11:00 AM – 12:15 AM CEST

**Presenter:** Larry W. Kwak, M.D., Ph.D.

**About PMB-CT01**

PMB-CT01 is a first-in-class BAFF-R-targeted autologous CAR T-cell therapy being
evaluated in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory
B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-
cell survival, reducing the likelihood of antigen-loss escape.

**About PeproMene Bio**

PeproMene Bio, Inc. is a clinical-stage biotech company in Irvine, California developing
novel therapies to treat cancers and immune disorders. For more information, contact
Hazel Cheng, Ph.D., COO of PeproMene Bio, Inc. at [Hazel.Cheng@pepromenebio.com](https://www.thailand-business-news.com/pr-news/Hazel.Cheng@pepromenebio.com)
or visit [https://pepromenebio.com/](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4696860-1&h=3503879462&u=https%3A%2F%2Fpepromenebio.com%2F&a=https%3A%2F%2Fpepromenebio.com%2F).

**Forward-Looking Statements**

This press release contains forward-looking statements subject to risks and uncertainties,
including risks related to clinical development, regulatory outcomes, therapeutic
potential, and commercialization. PeproMene Bio, Inc. undertakes no obligation to
update forward-looking statements except as required by law.

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure ](http://www.prnasia.com/story/archive/4968247_AE68247_0?rand=184833)